ROS1 and glioma: In our data, KLC1-ROS1 fusion-expressing glioma cells efficiently exerted oncogenic properties compared with wild-type ROS1 expressed glioma cells, especially under serum-reduced conditions (Figure 5a), which was suggested to be triggered by the KLC1 domain-mediated constitutive serum-independent self-oligomerization of KLC1-ROS1 fusion.